News

BioBlast is currently conducting a Phase 2 study in patients suffering from SCA3 in Israel. Cabaletta is a chemical chaperone that has been shown to prevent pathological aggregation

The acquisition further enhances BSN medical’s comprehensive product portfolio for the management of lymphatic and venous disorders under the JOBST and Elvarex brands. "This acquisition benefits BSN and

Pursuant to the amendment, Sandoz will increase its commercial investment in KERYDIN in 2015, and Anacor will contribute $20 million to Sandoz, primarily focused on consumer-directed commercialization activities.

Dextromethorphan is designed to treat cough due to minor throat and bronchial irritation. As part of the deal, Tris will be responsible for manufacturing and regulatory activities, while

Trevyent is SteadyMed’s lead drug product candidate currently under development stage that combines its PatchPump technology with treprostinil, a vasodilatory prostacyclin analogue to treat PAH. As part of

The deal will see the firms use T cell therapeutic strategies to develop treatments for these patients with an initial focus on Chimeric Antigen Receptor Technology (CAR-T) and

Currently, Tivorbex capsules are now available by prescription at pharmacies across the country. Tivorbex 20mg and 40mg dosage strengths are 20% lower than the 25mg and 50mg indomethacin

TriCalm Hydrogel was the company’s initial product in itch-relief product line and these two new products strategically expand the brand’s line of steroid-free, anti-itch products to further benefit

Spinifex is focused on developing a peripheral approach to treat neuropathic pain such as EMA401, a new angiotensin II Type 2 receptor (AT2R) antagonist. EMA401 is being developed